Serial analysis of CTCs may provide biomarker predictive of NSCLC response to crizotinib
Bottom Line: Among patients with non-small cell lung cancer (NSCLC) fueled by ALK gene alterations who were being treated with crizotinib (Xalkori), a decrease in...





